Navigation Links
Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
Date:9/11/2009

CINCINNATI, Sept. 11 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that its regulatory affairs experts will share their insights on key industry topics at the Regulatory Affairs Professionals Society (RAPS) Annual Conference and Exhibition to be held Sept. 13-16 at the Pennsylvania Convention Center in Philadelphia. Demonstrating its leadership position in providing regulatory guidance to its global pharmaceutical customers across the Phase I through IV clinical development process, Kendle has been selected to lead five sessions at the conference.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO)

Kendle's presentations include:

"New Pregnancy and Lactation Labeling Rule Revisions"

Monday, Sept. 14, 11 a.m.-Noon

Lisa Jenkins, PhD, Group Leader, Regulatory Consulting and Submissions

"Drug/Biologic Preapproval Inspection (PAI) - A Survival Guide"

Monday, Sept. 14, 1:30-3 p.m.

Hari Nagaradona, PhD, Associate Director, Regulatory Consulting and Submissions

"Adaptive Clinical Trial Designs That Get Results"

Monday, Sept. 14, 1:30-3 p.m.

Lisa Jenkins, PhD, Group Leader, Regulatory Consulting and Submissions

"The Expanding Role of Regulatory Advice: Guidance meets Business Development Professional " - Panel Discussion

Monday, Sept. 14, 1:30-3 p.m.

William Sietsema, PhD, Vice President, U.S. Regulatory Consulting and Submissions

"Ethical Standards in Clinical Research"

Tuesday, Sept. 15, 3:30-5 p.m.

William Sietsema, PhD, Vice President, U.S. Regulatory Consulting and Submissions

Kendle at Booth #706

Kendle experts will be available for on-site meetings and to discuss the Company's full suite of regulatory affairs capabilities at booth #706 in the exhibition hall.

Kendle offers extensive regulatory affairs experience, including delivery of all types of projects from global submissions to specialist consulting services. The Company provides expertise and advice at every stage of the drug development process, from early development to market and beyond. Kendle can ensure a product's development is conducted efficiently and in a timely manner, ensuring its smooth transition into the marketplace. The Company's Regulatory Affairs experts understand the commercial imperatives underlining decisions such as where to submit first, or which regulatory route to follow in a particular region, and work with biopharmaceutical companies worldwide to design an appropriate strategy for any product anywhere in the world.

Kendle offers customers global regulatory centers of expertise around the world to meet their needs. These integrated locations include Rockville, Maryland and Cincinnati, Ohio in the United States; Ely, England and Edinburgh, Scotland in Europe; Sydney and Melbourne, Australia in the Asia/Pacific region; and Mexico City, Mexico in Latin America.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
2. H3N2 Influenza Unlikely to Spread Between Humans, K-State Infectious Disease and Diagnostics Experts Say; Swine Exhibits at Fairs are Safe With Proper Hygiene
3. Leading Experts Endorse Biohearts Muscle Stem Cell MyoCell Therapy
4. SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts
5. Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide
6. Quality Colonoscopy Exam Remains Best Strategy for Detection of Polyps and Cancers According to Experts From the American College of Gastroenterology
7. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
8. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
9. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016 Spain Glaucoma Surgery Devices ... report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Canaloplasty Micro Catheters and Glaucoma ... and distribution shares data for each of these market ...
(Date:12/5/2016)... Special purpose needles are used in target specific ... cells from organs or lumps and are available in the ... market for special purpose needles is showing a steady growth ... the global special purpose needles market is projected to expand ... and is expected to be valued at US$ 17,261.5 million ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Institute for the Commercialization of Public Research ... finalized a funding agreement SegAna, LLC, an ... at University of Central Florida. The Florida Institute ... and bridges early funding gaps for companies spinning ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... of its latest transitional care facility – Avamere Transitional Care of Puget ... square foot short-term, post-acute health care center will provide patients recovering from illness ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... 70th Annual Meeting through tomorrow, December 6th, sparks a conversation about epilepsy, bearing ... , One in 26 people will be diagnosed with epilepsy within their lifetime. ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... Keynote speaker for the 21st Annual International Congress on Hematologic Malignancies®: Focus on ... PER® president, Phil Talamo said, “We are honored to have Amy E. Herman ...
Breaking Medicine News(10 mins):